Author: Decourt Boris
Publisher: Informa Healthcare
ISSN: 1369-1635
Source: Platelets, Vol.24, Iss.3, 2013-05, pp. : 235-238
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
To date there is no validated peripheral biomarker to assist with the clinical diagnosis of Alzheimer's disease (AD). Platelet proteins have been studied as AD biomarkers with relative success. In this study, we investigated whether platelet BACE1 levels differ between AD and cognitively normal (CN) control patients. Using a newly developed ELISA method, we found that BACE1 levels were significantly lower in AD compared to CN subjects. These data were supported by the observation that several BACE1 isoforms, identified by Western blotting, were also lower in AD platelets. This proof-of-concept study provides evidence for testing platelet BACE1 levels as a peripheral AD biomarker using a novel, sensitive and inexpensive method.
Related content
ADAM10 as a Biomarker for Alzheimer’s Disease: A Study with Brazilian Elderly
Dementia and Geriatric Cognitive Disorders, Vol. 35, Iss. 1-2, 2013-01 ,pp. :
By O’Sullivan Mary M. Brandfield Julie Hoskote Sumedh S. Segal Shiri N. Chug Luis Modrykamien Ariel Eden Edward
Journal of Asthma, Vol. 49, Iss. 9, 2012-11 ,pp. :